TFG Asset Management GP Ltd Buys 185,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

TFG Asset Management GP Ltd grew its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report) by 30.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 800,000 shares of the company’s stock after buying an additional 185,000 shares during the quarter. Tarsus Pharmaceuticals makes up 3.9% of TFG Asset Management GP Ltd’s portfolio, making the stock its 13th largest position. TFG Asset Management GP Ltd owned about 2.42% of Tarsus Pharmaceuticals worth $16,200,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TARS. RTW Investments LP raised its holdings in shares of Tarsus Pharmaceuticals by 9.4% in the 4th quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock valued at $63,835,000 after purchasing an additional 271,640 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $723,000. Swiss National Bank raised its holdings in shares of Tarsus Pharmaceuticals by 41.5% in the 3rd quarter. Swiss National Bank now owns 49,433 shares of the company’s stock valued at $878,000 after purchasing an additional 14,500 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $4,339,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 362.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock valued at $78,000 after buying an additional 3,004 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 4,436 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the sale, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the sale, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Seshadri Neervannan sold 4,879 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the sale, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The disclosure for this sale can be found here. Insiders have sold 24,496 shares of company stock valued at $749,578 in the last quarter. Insiders own 8.25% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded up $0.72 during trading on Wednesday, reaching $33.32. 177,391 shares of the company’s stock traded hands, compared to its average volume of 674,106. The company has a market capitalization of $1.26 billion, a P/E ratio of -6.83 and a beta of 1.10. The company has a current ratio of 8.01, a quick ratio of 7.92 and a debt-to-equity ratio of 0.11. The firm’s 50-day moving average is $34.93 and its 200 day moving average is $29.43. Tarsus Pharmaceuticals, Inc. has a 1 year low of $12.57 and a 1 year high of $42.50.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.14. The company had revenue of $27.61 million during the quarter, compared to the consensus estimate of $17.94 million. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.92 EPS for the current year.

Analyst Ratings Changes

TARS has been the subject of several research reports. Barclays increased their price objective on shares of Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, May 10th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, May 9th. HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the company a “buy” rating in a research note on Monday, May 13th. The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. Finally, Jefferies Financial Group lifted their price target on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.38.

Read Our Latest Stock Report on TARS

Tarsus Pharmaceuticals Company Profile

(Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Articles

Institutional Ownership by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.